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Blood pressure and long-term mortality in United States hemo- Hypertension and cardiovascular disease are notable
dialysis patients: USRDS Waves 3 and 4 Study. features of chronic kidney disease. Only a few recent ob-
Background. The long-term prognostic associations of pre- servational studies, surprisingly, have associated hyper-
and post-dialysis blood pressures, interdialytic weight gain, and
tension and shorter survival in dialysis patients [1, 2].antihypertensive use in hemodialysis patients are unclear.
Most studies have shown an association between lowMethods. The United States Renal Data System (USRDS)
Dialysis Morbidity and Mortality Waves 3 and 4 Study, a ran- blood pressure and increased mortality, or have shown
domly generated sample of 11,142 subjects receiving hemodial- a “U”-shaped relationship, with both low and high blood
ysis on December 31, 1993, was examined, with vital status fol- pressure being associated with an increased relative risk
lowed until May 2000.
of death [3–6]. A credible explanation for the findings isResults. Pre- and post-dialysis blood pressure values, interdi-
that the patient sample includes a sizeable proportion ofalytic weight gain and number of antihypertensives averaged
patients with incipient or established cardiac decompen-151.8/79.7, 137.0/74, 3.6% and 0.76, respectively. Prognostic dis-
crimination was maximized by considering pre- and post-sys- sation, with the counterintuitive relationship between
tolic and diastolic blood pressure values simultaneously, in a lower blood pressure and survival caused by reverse cau-
pattern suggesting that wide pulse pressures were associated sation. Alternative explanations than reverse causation
with mortality (P 0.0001). Comorbidity adjustment markedly
are possible, however. It is conceivable that low bloodaffected associations, with low pre-dialysis diastolic (P 0.05),
pressure could jeopardize coronary perfusion in the set-low post-dialysis dialysis diastolic pressure (P  0.05), high
post-dialysis dialysis systolic pressure (P  0.05), and high ting of the altered cardiac energetics, diastolic dysfunc-
interdialytic weight gains (P 0.005) associated with mortality. tion, and decreased capillary density so characteristic of
Each class of antihypertensive drug, except angiotensin-con- uremic cardiomyopathy, leading to myocardial ischemia.
verting enzyme (ACE)-inhibitors, was associated with lower Ischemia would be magnified in the presence of fixedmortality in unadjusted models, an effect most pronounced for
coronary stenosis, a common entity, which is often clini-beta-blockers (hazards ratio 0.72, 95% CI 0.66 to 0.79, P 
cally silent in dialysis patients.0.0001). Comorbidity adjustment eliminated survival associa-
tions for each antihypertensive class except beta-blockers. To date, almost all mortality analyses in end-stage renal
Conclusions. Pre- and post-dialysis blood pressure values have disease patients have used either systolic blood pressure,
independent associations with mortality, in a way that impli- or diastolic blood pressure as the candidate variable.
cates wide pulse pressures. Much of the adverse prognosis of
Most analyses have focused on pre-dialysis blood pres-wide pulse pressures probably reflects older age and cardio-
sure, and very few have examined the prognostic associa-vascular comorbidity. Large interdialytic weight gains are asso-
tions of post-dialysis blood pressures. Very few epidemi-ciated with shorter survival when comorbidity is taken into
account. Beta-blocker use shows a robust association with sur- ological studies have attempted to quantify the relative
vival, and may be protective. contributions of blood pressures, interdialytic weight
gains, and the number and classes of antihypertensives
used, all of which are clearly interrelated.
1 The data reported here were supplied by the United States Renal
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Table 1. Patient characteristics on December 31, 1993 (N  11,142)pulse pressure and mortality. On the other hand, using
pulse pressure in isolation may create an artifactual asso- Mean (SD) Missing data
ciation when high systolic blood pressure or low diastolic Age years 59.7 (15.8) 13.1%
Gender 0.1%blood pressure is the real culprit, and pulse pressure has
Male 50.7%no causal relationship. Such problems can be uncovered
Female 49.2%
when two of the three parameters (systolic, diastolic and Race
Hispanic 13.1% 6.3%pulse pressure) are included simultaneously in mortality
Caucasian 51.0% 6.4%analyses, an approach used recently in studies in the both
African American 41.0%
the general and end-stage renal disease populations [8, 9]. Asian 2.3%
Native American 1.5%
Other 4.2%
Primary renal disease 7.3%METHODS
Diabetes 34.3%
The objectives of this study were to determine (1) the Hypertension 29.6%
Primary glomerulonephritis 11.5%optimum way to handle blood pressure parameters for
Other 4.2%a hemodialysis population, in a way that maximizes prog-
Unknown 20.5%
nostic discrimination, as described by the 2 statistic in Smoking status 17.2%
Still smoking 16.1%Cox regression models of mortality; (2) the mortality
Former, stopped 1 year ago 2.7%associations of interdialytic weight gains; (3) the mortal- Former, stopped 1 year ago 14.2%
ity associations of classes of antihypertensive used; and Smoker, current status unknown 14.4%
Non-smoker 52.6%(4) the impact of comorbidity adjustment on objectives
Diabetes mellitus 42.9% 8.8%1 to 3. Cardiovascular disease
We used the United States Renal Data System (USRDS) Coronary artery disease 36.0% 12.4%
Congestive heart failure 39.2% 12.2%DMMS Waves 3 and 4 Study, a historical prospective
Peripheral vascular disease 22.1% 11.7%study of a randomly generated sample of 11,142 United Cerebrovascular disease 12.5% 11.7%
States subjects receiving hemodialysis at the end of De- Duration of hemodialysis years 3.1 (3.5) 14.2%
Pre-dialysis blood pressure mm Hg 151.8 (22.1)/ 11.2%/cember 1993. Participating dialysis units were selected
79.7 (12.2) 11.5%at random, with case records reviewed retrospectively. Post-dialysis blood pressure mm Hg 137.0 (21.0)/ 11.6%/
For this study, the following fixed patient characteristics 74.1 (11.3) 11.9%
Interdialytic weight gain % 3.6 (1.9) 15.6%were included, as of December 31, 1993: age, gender, eth-
Calcium channel antagonists 35.0% Assumeda 0%nicity, race, primary renal disease, duration of hemodial- Angiotensin-converting enzyme inhibitors 13.9% Assumeda 0%
ysis, smoking, diabetic status, presence of coronary artery Beta blockers 8.5% Assumeda 0%
Alpha blockers 3.4% Assumeda 0%disease or coronary heart disease, congestive heart fail-
Centrally active agents 9.8% Assumeda 0%
ure, cerebrovascular accident and peripheral vascular Vasodilators 5.1% Assumeda 0%
disease. a All medications were recorded in 15 data-fields. Dichotomous ‘yes’ or ‘no’
variables asking whether specific drug classes were used were not used.Pre- and post-dialysis blood pressures, and interdia-
lytic weight gains were averaged from the three most
recent values immediately preceding December 31, 1993.
Vasoactive medications were grouped into the following
79.7 and 137.0/74.1 mm Hg equating to pulse pressuresclasses: calcium channel blockers, angiotensin-convert-
of 72.1 and 62.9 mm Hg, respectively. On average, inter-ing enzyme (ACE) inhibitors, beta blockers, alpha block-
dialytic weight gain was 3.6% of pre-dialysis body weight,ers, centrally active agents, and vasodilators.
and the patients were prescribed 0.76 antihypertensiveUSRDS patient numbers were used to combine the
agents. A percentage of 49.6% of patients were pre-DMMS Waves 3 and 4 file with the Patient’s file, with
scribed no antihypertensive agents, 30.9% one agent,vital status ascertained up to May 2000. Cox proportional
14.7% two agents, 3.9% three agents, 0.8% four agents,hazards modeling was the primary analytical tool em-
and 0.1% five agents. Calcium channel antagonists (35.0%ployed. The analyses presented in this report did not
of patients) were the most frequently prescribed class,censor patients at transplantation. However, the associa-
followed by ACE inhibitors (13.9%), centrally actingtions were virtually identical with such an approach.
agents (9.8%), beta blockers (8.5%), vasodilators (5.1%),
and alpha blockers (3.4%).
RESULTS Sixty-three percent of the subjects died over an aver-
age follow-up of 3.8 years, with a median survival of 3.9The patient characteristics on December 31, 1993 are
years. Figure 1 shows hazards ratios and the overallshown in Table 1. The mean pre- and post-dialysis blood
model 2 statistics in Cox regression models of mortalitypressures, averaged from the three most recent values
immediately preceding December 31, 1993, were 151.8/ which have not been adjusted for age or comorbidity.
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lently higher for second, third and fourth quintiles, with
a further rise in hazards ratio for the fifth quintile. Per-
centage of interdialytic weight gain exhibited a weak in-
verse association with mortality in unadjusted analyses.
Each antihypertensive class, except ACE inhibitors, was
associated with statistically significantly longer survival.
This effect was greatest for beta blocker use (hazards
ratio 0.72, 95% CI 0.66 to 0.79, P 0.0001) and vasodila-
tor use (hazards ratio 0.73, 95% CI 0.65 to 0.82, P 
0.0001).
When an adjustment was made for comorbidity, low
pre-dialysis diastolic, low post-dialysis diastolic, and high
post-dialysis systolic blood pressure values were associ-
ated with higher mortality, albeit much less strongly than
in unadjusted models. Percentage interdialytic weight
gain, on the other hand, showed a direct association with
mortality, most apparent for weight gains in the highest
quintile, greater than 4.8% of pre-dialysis body weight.
All classes of antihypertensive lost their mortality associ-
ations in comorbidity-adjusted models, with the excep-
tion of beta-blockers, which retained their association
with lower mortality rates (hazards ratio 0.84, 95% CI
0.75 to 0.93, P  0.001).
DISCUSSION
Considering pre- and post-systolic and -diastolic blood
Fig. 1. (A) Cox regression models relating blood pressure levels to
pressure values simultaneously maximized the prognos-subsequent mortality rates, expressed as hazards ratios per 10 mm Hg.
Symbols are: () pre-dialysis parameters; () post-dialysis parameters. tic discrimination in this study, in a pattern suggesting that
Abbreviations are: S, systolic blood pressure; D, diastolic blood pres- wide pulse pressure may be a marker of short survival.
sure; Alone, only that single parameter was entered in the Cox model;
Adjustment for older age and comorbidity greatly modi-together, all of the parameters shown were entered simultaneously in
the model. Hazards ratios greater than 1 imply higher mortality rates, fied these associations. Similarly, complex associations
while hazards ratios less than 1 imply lower mortality rates. ***P  were found between interdialytic weight gain and mor-
0.0001; **P 0.001; *P 0.05. (B) Cox regression models relating blood
tality, with shorter associated survival apparent after co-pressure levels to subsequent mortality rates. The columns show the
variance explained, expressed as the associated 2 statistic for different morbidity adjustment. Finally, we observed that beta-
models. Symbols are: () models with only pre-dialysis parameters; blocker use was associated with longer survival, whether
() models with only post-dialysis parameters; ( ) models with both
or not comorbidity adjustment was undertaken.pre-dialysis and post-dialysis parameters.
Hypertension in the general population increases the
long-term risk of end-stage renal disease [10, 11]. Among
patients with renal impairment, strategies that lower
Judged in terms of the 2 value, the prognostic discrimi- blood pressure, including ACE inhibitors and angioten-
nation was maximized by analyzing diastolic and systolic sin II receptor inhibitors, are known to retard the rate
blood pressure values simultaneously, both before and of loss of renal function, and to delay the onset of end-
after dialysis. In the latter models, the hazards ratios stage renal disease [12–17]. It is likely that blood pressure
for systolic blood pressures increased, while those for reduction per se contributes to these salutary effects [18].
diastolic blood pressures decreased, suggesting that wide Hypertension is an almost universal feature of end-stage
pulse pressure may be a better marker of mortality risk renal disease, and this group of patients is at the highest
than systolic or diastolic blood pressure in isolation. cardiac risk. Unfortunately, there are no large hyperten-
The associations between blood pressure, related vari- sion-management trials in dialysis patients. It could be
ables, and mortality are shown in Table 2. All four blood argued that such trials might not be needed if the epide-
pressure variables, that is, pre- and post- systolic and miological patterns linking blood pressure and outcome
diastolic values, were entered simultaneously. When an- in the dialysis population were similar to those seen in
alyzed by quintiles, all relationships tended to be mono- the general population. Most recent studies, however,
tonic, with the possible exception of pre-dialysis systolic have been at variance to those seen in non-renal popula-
tions, with inverse or “U”-shaped relationships with mor-blood pressure, for which the hazards ratios were equiva-
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Table 2. Blood pressure and mortality associations
Unadjusted hazards ratioa Adjusted hazards ratiob
Pre-dialysis DBPc 0.79 (0.76, 0.82) per 10 mm Hg 0.95 (0.91, 0.99) per 10 mm Hg
Quintiles P  0.0001 P  0.03
70 1.06 (reference category) 1 (reference category)
70.1 to 76.7 0.79 (0.73, 0.85) 0.90 (0.82, 0.98)
76.8 to 82.0 0.73 (0.67, 0.79) 0.97 (0.88, 1.07)
82.1 to 89.3 0.64 (0.59, 0.71) 0.94 (0.84, 1.05)
89.3 0.49 (0.44, 0.55) 0.90 (0.77, 1.02)
Pre-dialysis SBPc 1.06 (1,04, 1.08) per 10 mm Hg 0.99 (0.97, 1.02) per 10 mm Hg
Quintiles P  0.0001 P  0.6
133.3 1 (reference category) 1 (reference category)
133.4 to 146.7 1.14 (1.05, 1.24) 0.97 (0.93, 1.01)
146.8 to 157.3 1.16 (1.06, 1.28) 0.89 (0.79, 0.99)
157.4 to 170.0 1.15 (1.04, 1.27) 0.87 (0.77, 0.97)
170.0 1.38 (1.22, 1.55) 0.96 (0.83, 1.10)
Post-dialysis DBPc 0.87 (0.76, 0.82) per 10 mm Hg 0.94 (0.90, 0.98) per 10 mm Hg
Quintiles P  0.0001 P  0.006
64.7 1 (reference category) 1 (reference category)
64.8 to 70.7 0.92 (0.85, 1.00) 0.95 (0.87, 1.05)
70.8 to 76.7 0.86 (0.79, 0.93) 0.95 (0.86, 1.05)
76.8 to 83.0 0.83 (0.75, 0.92) 0.93 (0.82, 1.04)
83.0 0.65 (0.57, 0.73) 0.85 (0.73, 0.99)
Post dialysis SBPc 3 (1.03, 1.08) per 10 mm Hg 1.03 (1.00, 1.05) per 10 mm Hg
Quintiles P  0.0001 P  0.03
119.3 1 (reference category) 1 (reference category)
119.4 to 130.7 1.11 (1.02, 1.21) 0.93 (0.84, 1.03)
130.8 to 141.3 1.15 (1.05, 1.27) 0.95 (0.85, 1.06)
141.4 to 154.0 1.22 (1.11, 1.35) 0.97 (0.86, 1.06)
154.0 1.31 (1.16, 1.47) 1.07 (0.93, 1.22)
Interdialytic weight gain 0.99 (0.97, 1.00) per % 1.02 (1.01, 1.03) per %
Quintiles P  0.05 P  0.005
2.3 (reference) 1 (reference category) 1 (reference category)
2.3 to 3.1 0.97 (0.90, 1.06) 0.96 (0.88, 1.05)
3.2 to 3.9 1.02 (0.94, 1.10) 1.03 (0.94, 1.13)
4.0 to 4.8 0.99 (0.91, 1.07) 1.03 (0.94, 1.14)
4.8 0.92 (0.85, 1.00) 1.12 (1.02, 1.23)
Calcium channel antagonistsd 0.95 (0.90, 1.00) 1.0 (0.94, 1.07)
P  0.04 P  0.9
Angiotensin-converting enzyme inhibitorsd 0.94 (0.88, 1.01) 1.05 (0.96, 1.17)
P  0.07 P  0.3
Beta blockersd 0.72 (0.66, 0.79) 0.84 (0.75, 0.93)
P  0.0001 P  0.001
Alpha blockersd 0.87 (0.77, 1.00) 0.93 (0.80, 1.09)
P  0.05 P  0.4
Centrally active agentsd 0.89 (0.82, 0.96) 4 (0.97, 1.17)
P  0.004 P  0.2
Vasodilatorsd 0.73 (0.65, 0.82) 0.99 (0.86, 1.14)
P  0.0001 P  0.9
a Hazards ratios greater than 1 imply higher mortality rates, while hazards ratios less than 1 imply lower mortality rates
b Adjusted for age, gender, ethnic status, race, cause of renal disease, duration of end-stage renal disease, smoking, diabetes, coronary artery disease, congestive
heart failure, peripheral vascular disease, and interdialytic weight gain
c Predialysis-SBP (systolic blood pressure), Predialysis-DBP (diastolic blood pressure); postdialysis-SBP and postdialysis-DBP have been included simultaneously
in the unadjusted and adjusted models
d Reference categories are subjects not on calcium channel antagonists, angiotensin-converting enzyme inhibitors, beta blockers, alpha blockers, centrally active
agents, and vasodilators, respectively
tality [3–6]. Few studies in end-stage renal disease pa- cordance regarding cause of death has been reported to
occur in approximately two out of every three cases intients have examined non-fatal cardiovascular end-points.
Some studies have tried to address this issue indirectly, one study, while a more recent study suggested that dis-
cordance may occur even more commonly for cardiovas-using cause-specific mortality in registry databanks. This
approach may not be very reliable, as inter-rater dis- cular causes of death [19, 20].
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In one long-term prospective inception cohort study, the fact that blood pressures were similar, suggesting an
independent impact of ACE inhibitors on left ventricularhigher time-averaged blood pressures predated the de-
velopment of echocardiographic left ventricular hyper- hypertrophy regression [32]. Similarly, another study
used ACE inhibitors as the primary antihypertensivetrophy, new-onset ischemic heart disease and new-onset
cardiac failure. In this latter study, new-onset cardiac fail- therapy in hemodialysis patients, and observed a gradual
regression of left ventricular hypertrophy over a periodure was a lethal event, which came before two-thirds of
all the observed causes of mortality, and was followed of several years [33]. Thus, the consistent association
between echocardiographic left ventricular hypertrophyby a fall in blood pressure. The degree of hypotension
was the only predictor of mortality after cardiac failure and mortality is at variance with the inconsistent associa-
tion between blood pressure and mortality in large regis-[21]. This is a plausible, though partial, explanation for
the paradox that high blood pressure comes before a try studies, as higher blood pressure levels have consis-
tently been associated with the development of leftmajor apparent killer, cardiac failure, while low blood
pressure is a better predictor of death. These data suggest ventricular hypertrophy.
Stiffening of the vascular tree appears to be a charac-that the association between high blood pressure and
longer survival may be due to reverse causality. Blood teristic feature of uremia, which has recently been dem-
onstrated to be highly predictive of short survival [7].pressure is a problematic parameter in dialysis studies with
several inherent limitations. Ambulatory blood pressure Widened pulse pressure, a clinical hallmark of vascular
rigidity, lately has become a focus of more intensive in-monitoring was not used in this study, but would have
an obvious attraction in comparison to single values im- vestigation. For example, a very interesting report from
the Framingham Heart Study suggests that parametersmediately before and after dialysis. For example, a recent
study performed 48-hour interdialytic ambulatory blood like systolic and diastolic blood pressures, in isolation,
have less predictive power in general population subjectspressure monitoring on 21 hemodialysis patients on two
different occasions two months apart. Blood pressure over 60, in whom high pulse pressures are more highly
predictive of adverse cardiovascular events [8]. Similarwas analyzed according to three different methods on
each occasion: isolated levels before and after dialysis, findings were reported from a French hypertensive popu-
lation [34]. If pulse pressure is indeed a superior prognos-levels averaged over five dialysis sessions, and 48-hour
interdialytic ambulatory blood pressure monitoring. tic discriminate, analyses that use either systolic or dia-
stolic blood pressures alone should have less predictiveVariability was considerable, even with ambulatory blood
pressure (the most reproducible measure of blood pres- power, while analyses that include both systolic and
blood pressure parameters simultaneously should havesure, followed by averages and single values), with coef-
ficients of variation 7.5% for systolic and 8.1% and dis- more predictive power. This pattern was seen in our cur-
rent study, which suggested that high pulse pressure,cordance rates for nocturnal dipper status of 43% [22].
Hypertension has been consistently associated with whether before or after dialysis, is a marker of short sur-
vival in dialysis, mostly, but not completely, as a markerleft ventricular enlargement in observational studies in
chronic renal insufficiency, which is likely to be a poten- of underlying comorbidity. These findings are consistent
with those recently reported by Tozawa and co-workers,tially reversible intermediate stage between cardiac health
and clinical cardiovascular disease, as is the case in the who examined a cross-section of 1243 chronic hemodial-
ysis patients alive on January 1, 1991 followed for ninegeneral population [23–27]. Hypertension in dialysis pa-
tients is often due to subclinical salt and water overload years [9]. Pulse pressure was found to be an independent
predictor of total mortality, and was a superior predictor[28–30]. For example, a recent crossover trial was re-
ported comparing short daily and conventional, three of total mortality than systolic or diastolic pressures. For
predicting cardiovascular events, however, systolic bloodtimes weekly hemodialysis sessions. Although weekly urea
removal was similar with either strategy, blood pressure pressure was better than either pulse pressure or diastolic
blood pressure [9]. In epidemiological analyses, pulsewas significantly better in the daily dialysis group, in
whom antihypertensives were discontinued in most pa- pressure is necessarily handled as a somewhat static pa-
rameter, in the sense that a single unique value exists fortients. Left ventricular hypertrophy regressed in the daily
hemodialysis group, probably due to lowering of extra- each study subject. However, from a pathophysiological
perspective, pulse pressure is clearly a composite param-cellular fluid volume [31]. A number of other studies have
shown that inexorable progression of left ventricular hy- eter determined by parameters of left ventricular ejec-
tion, opposition to ejection, and wave reflections. Thus,pertrophy is not inevitable in dialysis patients. In one
study, dialysis patients with left ventricular hypertrophy the pathways to a given pulse pressure must be very di-
verse in the population examined in this study. It isand hypertension were randomly assigned to an ACE
inhibitor or a dihydropyridine calcium antagonist for believed that in older subjects the wide pulse pressure
reflects increased stiffness, a characteristic feature ofone year. Left ventricular hypertrophy regressed in both
groups, but more so in the ACE inhibition group, despite end-stage renal disease patients, which accelerates dia-
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stolic decay rates, leading to lower diastolic blood pres- tions, especially when multiple strategies, both phar-
macological and non-pharmacological, can be used tosure and wider pulse pressure [35].
It has long been a doctrine of dialysis treatment that achieve a given blood pressure level. Similarly, a given
antihypertensive class may be used more as the treat-blood pressure and extracellular fluid volumes are closely
related. It makes intuitive sense that patients who will ment for ischemic heart disease, cardiac failure, systolic
dysfunction or left ventricular hypertrophy, all of whichdevelop overt cardiovascular disease in the future may
not exhibit symptoms of cardiac decompensation with are common in dialysis patients.
Randomized controlled trials are sorely needed in di-higher interdialytic fluid gains. Our current study suggests
that interpreting the relationship between interdialytic alysis populations to define optimal strategies for manag-
ing blood pressure. It is possible that relatively recentfluid gains and mortality is heavily dependent on consid-
ering the underlying comorbidity of the population. observational studies linking higher blood pressures to
longer survival have engendered therapeutic uncertaintyWe observed an association between beta-blocker use
and longevity in this study, an association that was only and neutrality, and lessened enthusiasm to undertake ade-
quately powered clinical trials. Blood pressure levels inpartly affected by comorbidity adjustment. Clearly, an
observational study like this cannot account for the se- a modern dialysis population are likely to reflect the
age and comorbidity of the population, deviations fromlection biases connecting different patients to different
classes of antihypertensive drugs, and cannot adduce euvolemia, and antihypertensive use. This study, in which
the follow-up period was long, suggests that high bloodcausality. However, beta blockers have several theoreti-
cally appealing features in uremic populations. They re- pressure (pulse pressure), high interdialytic weight gains,
and not being on antihypertensives (beta blockers) defineduce stroke volume and thus would be attractive agents
to interrupt the vicious cycle whereby high stroke vol- a dialysis population at high risk, which may be modifiable.
umes and large vessel rigidity exacerbate each other.
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